secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-06-01T23:40:29+00:00
Accession:  0001493152-26-026696
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300
----------------------------------------------------------------------------

- Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.
- No specific trial results or financial data disclosed in the 8-K filing itself.
- Investors must review the presentation exhibit for detailed clinical updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226026696/0001493152-26-026696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226026696/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-026696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer